Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Single-agent inhibitors of phosphatidylinositol-3-kinase (PI3K) and bromodomain and extraterminal (BET) bromodomains show limited efficacy in lymphoma with c-MYC dysregulation.
• Compensatory epigenetic and signaling networks contribute to resistance against single-agent therapies.
• Combined inhibition strategies are needed to overcome these resistance mechanisms.

Purpose of the Study:

• To mechanistically and therapeutically validate rationally designed dual PI3K/BET bromodomain inhibitors.
• To evaluate the efficacy of combined PI3K and BET inhibition in preclinical lymphoma models.
• To explore a novel therapeutic strategy for MYC-driven lymphomas.

Main Methods:

• Design and synthesis of chimeric small molecules linking PI3K and BET inhibitor pharmacophores.
• In vitro assessment of selectivity and cellular potency (nanomolar range).
• In vivo efficacy studies in aggressive Eµ-Myc lymphoma models.

Main Results:

• The lead dual inhibitor candidate demonstrated high selectivity and potent cellular activity.
• Compelling in vivo efficacy was observed, including curative responses in aggressive lymphoma models.
• The combined inhibition strategy showed synergistic anticancer activity.

Conclusions:

• Combined PI3K and BET inhibition is a therapeutically viable strategy for lymphoma.
• Optimized chimeric small-molecule technology offers a novel approach to orthogonal MYC antagonism.
• These findings support a potential step-change in the treatment of c-MYC-dysregulated lymphomas.